CureLab CEO Cites 3 Next-Gen Immunotherapy Shifts, Says Phase II Trial Doubled Survival
Updated
Updated · BSA bureau · Jun 25
CureLab CEO Cites 3 Next-Gen Immunotherapy Shifts, Says Phase II Trial Doubled Survival
1 articles · Updated · BSA bureau · Jun 25
Summary
Alex Shneider said next-generation cancer immunotherapy is moving beyond attacking single tumor cells toward rewiring the biological systems that let cancer survive, highlighting DNA/RNA delivery, dynamic vectors and tumor-microenvironment remodeling.
He argued chronic inflammation has become a central target because it drives immune evasion and treatment resistance, saying the goal is to turn “cold” tumors “hot” rather than broadly suppress immunity.
Shneider pointed to CureLab’s randomized Phase II trial in platinum-resistant ovarian cancer, where adding its inflammation-modulating plasmid to chemotherapy more than doubled median overall survival with zero treatment-related serious adverse events.
On combinations, he said brute-force testing is unworkable—5 agents create more than 30 combinations, 10 more than 1,000 and 30 over 1 billion—making biology-guided pairing and scheduling the next decade’s priority.
He also said emerging biotech hubs in Asia-Pacific and other regions can expand trial capacity, manufacturing and capital, helping smaller companies generate data before entering costlier U.S. and European pathways.
With DNA therapies becoming 'intelligent,' will the biggest profits come from the drug itself or the AI that designs and controls it?
As therapies reprogram entire biological systems, what safeguards can prevent unintended consequences far beyond the original tumor?
Will new global biotech hubs make these treatments more accessible, or create a new tier of ultra-expensive medicine?
Elenagen’s Phase II Success: Doubling Survival in Platinum-Resistant Ovarian Cancer and Redefining Immunotherapy
Overview
The recent Phase II clinical trial results for Elenagen mark a major step forward for women with platinum-resistant ovarian cancer. This investigational DNA therapy has shown a strong ability to improve patient outcomes and offers hope where few options exist. The trial found that longer exposure to Elenagen is linked to better survival rates, with analyses confirming this effect. Patients who received the therapy for extended periods experienced improved survival, suggesting a duration-response relationship. These findings highlight Elenagen’s potential to address a critical unmet need in oncology, combining clinical benefit with a favorable safety profile.